Abstract
Most of the current drugs are approved and developed based on their performance in a large population of people but medicine of the future is developing as personalized solutions for a particular patient’s needs. In case of complex disorders, the conventional “one-drug-fits-all” approach involves trial and error before an appropriate treatment is found. Clinical trial data for a new drug merely shows the average response of a study group. There is, however, considerable individual variation; some patients show no response whereas others show a dramatic response. It is obvious that the concept “one medicine for all patients with the same disease” does not hold and a more individualized approach is needed. Although individualization of certain treatments has been carried out in the pregenomic era, the concept of personalized medicine as described in this report follows progress in study of human diseases at molecular level, advances in molecular diagnostics and drug development based on genomics, proteomics, metabolomics and biomarkers. The aim of the personalized medicine is to match the right drug to the right patient and in some cases, even to design the treatment for a patient according to genotype as well as other individual characteristics. A broader term is integrated healthcare, which includes development of genomics-based personalized medicine, predisposition testing, preventive medicine, combination of diagnostics with therapeutics and monitoring of therapy. This fits in with the concept of system biology as applied to healthcare and termed systems medicine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Beutler E, Dern RJ, Alving AS. The hemolytic effect of primaquine. VI. An in vitro test for sensitivity of erythrocytes to primaquine. J Lab Clin Med. 1955;45:40–50.
Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326:1509–12.
Bousquet J, Jorgensen C, Dauzat M, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des. 2014;20:5928–44.
Chae H, Park SH, Lee SJ, et al. Sasang typology from a personality perspective. J Korean Orient Med. 2004;25:151–64.
Chopra A, Doiphode VV. Ayurvedic medicine. Core concept, therapeutic principles, and current relevance. Med Clin North Am. 2002;86:75–89.
Conrad DF, Pinto D, Redon R, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464:704–12.
Ezkurdia I, Juan D, Rodriguez J, et al. Multiple evidence strands suggest that there may be as few as 19000 human protein-coding genes. Hum Mol Genet. 2014;23:5866–78.
Fahy GM. Molecular nanotechnology. Clin Chem. 1993;39:2011–6.
Fisher MA, McKinley KL, Bradley LH, et al. De novo designed proteins from a library of artificial sequences function in Escherichia coli and enable cell growth. PLoS One. 2011;6(1):e15364.
Galas DJ, Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. IBC. 2009;1:6.
Garrod AE. The inborn factors in disease. London: Oxford University Press; 1931.
Gibson DG, Glass JI, Lartigue C, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 2010;329:52–6.
Girirajan S, Rosenfeld JA, Cooper GM, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42:203–9.
Girirajan S, Rosenfeld JA, Coe BP, et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N Engl J Med. 2012;367:1321–31.
Goldberger JJ, Buxton AE. Personalized medicine vs guideline-based medicine. JAMA. 2013;309:2559–60.
Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet. 2009;10:551–64.
Jain KK. Health care in New China. Emmaus: Rodale Press; 1973.
Jain KK. Personalized medicine. Waltham: Decision Resources Inc; 1998.
Jain KK. Personalised medicine. Curr Opin Mol Ther. 2002;4:548–58.
Jain KK. Synthetic biology and personalized medicine. Med Princ Pract. 2013;22:209–19.
Kalow W. Familial incidence of low pseudocholinesterase level. Lancet. 1956;2:576–7.
Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia: Saunders; 1962.
Kidd JM, Cooper GM, Donahue WF, et al. Mapping and sequencing of structural variation from eight human genomes. Nature. 2008;453:56–64.
Korbel JO, Urban AE, Affourtit JP, et al. Paired-end mapping reveals extensive structural variation in the human genome. Science. 2007;318:420–6.
Lee KH, Chiu S, Lee YK, et al. Age-dependent and tissue-specific structural changes in the C57BL/6J mouse genome. Exp Mol Pathol. 2012;93:167–72.
Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA. Clan genomics and the complex architecture of human disease. Cell. 2011;147:32–43.
Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol. 1997;15:829–30.
Mills RE, Luttig CT, Larkins CE, et al. An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res. 2006;16:1182–90.
Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366:489–91.
Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA. 1957;165:835–7.
Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986;51:263–73.
Nielsen J. Translational and systems medicine. J Int Med. 2012;271:108–10.
Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444:444–54.
Romanoski CE, Lee S, Kim MJ, et al. Systems genetics analysis of gene-by-environment interactions in human cells. Am J Hum Genet. 2010;86:399–410.
Skipper M, Dhand R, Campbell P. Presenting ENCODE. Nature. 2012;489:45.
Solomon BD, Nguyen AD, Bear KA, Wolfsberg TG. Clinical genomic database. Proc Natl Acad Sci U S A. 2013;110:9851–5.
Sudmant PH, Kitzman JO, Antonacci F, et al. Diversity of human copy number variation and multicopy genes. Science. 2010;330:641–6.
Vandamme D, Fitzmaurice W, Kholodenko B, Kolch W. Systems medicine: helping us understand the complexity of disease. QJM. 2013;106:891–5.
Vogel F. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd. 1959;12:52–125.
Watson JD, Crick FHC. Genetic implications of the structure of deoxyribonucleic acid. Nature. 1953;171:964–9.
Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects: why all proteins expressed by genome should be identified and how to do it. Biotechnol Genet Eng Rev. 1995;13:19–50.
Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: a future perspective. Genome Med. 2009;1:11.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jain, K.K. (2015). Basic Aspects. In: Textbook of Personalized Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2553-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2553-7_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2552-0
Online ISBN: 978-1-4939-2553-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)